United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland. Show more

Location: 1000 Spring Street, Silver Spring, MD, 20910, United States | Website: https://www.unither.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

13.33B

52 Wk Range

$266.98 - $417.82

Previous Close

$300.16

Open

$298.19

Volume

300,699

Day Range

$295.33 - $298.96

Enterprise Value

9.84B

Cash

3.321B

Avg Qtr Burn

N/A

Insider Ownership

1.75%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tyvaso (inhaled treprostinil) Details
Pulmonary Hypertension (PH) WHO Group 3

Approved

Quarterly sales

Tyvaso DPI™ (inhaled treprostinil) Details
Pulmonary Hypertension (PH) WHO Group 1 / (PAH)Pulmonary Hypertension (PH) WHO Group 3

Approved

Quarterly sales

Remunity™ (treprostinil) Details
Pulmonary Hypertension (PH) WHO Group 1 (PAH)

Approved

Quarterly sales

Tyvaso (inhaled treprostinil) Details
Progressive pulmonary fibrosis

Phase 3

Data readout

Ralinepag Details
Pulmonary arterial hypertension (PAH)

Phase 3

Data readout

Tyvaso (inhaled treprostinil) Details
Pulmonary fibrosis, Idiopathic pulmonary fibrosis

Phase 3

Data readout

miroliverELAP Details
Acute liver failure

Phase 1

Data readout

UKidney™ Details
End-stage renal disease

Phase 1

Initiation

Trevyent® (treprostinil sodium) Details
Pulmonary Hypertension (PH) WHO Group 1 (PAH)

Failed

Discontinued

Tyvaso (inhaled treprostinil) Details
Pulmonary hypertension, Chronic obstructive pulmonary disease

Failed

Discontinued